Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients

Table 3

Stratification analysis of P2RY12 polymorphisms in KD cases who were resistant or sensitive to IVIG therapy.

Variable

rs6809699 (IVIG R/IVIG S)

value^a

OR (95% CI)

value

Adjusted OR (95% CI)

value^b

Combined analysis^c (IVIG R/IVIG S)

value^a

OR (95% CI)

value

Adjusted OR (95% CI)

value^b

AA

AC/CC

0–3

4–5

Age, months

≤60

121/460

13/119

0.0019

0.42 (0.23–0.76)

0.0045

0.42 (0.23–0.76)

0.0045

128/479

6/100

<0.0001

0.23 (0.10–0.52)

0.0005

0.22 (0.10–0.52)

0.0005

>60

11/27

3/5

0.6378

1.47 (0.30–7.25)

0.6340

1.39 (0.28–6.99)

0.6898

12/28

2/4

0.8695

1.17 (0.19–7.25)

0.8687

1.02 (0.16–6.55)

0.9805

Gender

Male

88/330

9/86

0.0055

0.39 (0.19–0.81)

0.0115

0.38 (0.19–0.80)

0.0100

92/347

5/69

0.0014

0.27 (0.11–0.70)

0.0066

0.27 (0.11–0.69)

0.0064

Female

44/157

7/38

0.3302

0.66 (0.28–1.57)

0.3464

0.66 (0.27–1.57)

0.3458

48/160

3/35

0.0202

0.29 (0.08–0.97)

0.0466

0.28 (0.08–0.96)

0.0430

^aTwo-sided χ² test for distributions between Kawasaki disease patients with IVIG resistance and IVIG sensitivity. ^bAdjusted for age and gender, stratified by gender (adjusted for age) and age (adjusted for gender). ^cCombined effect of protective genotypes.